Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV000503801 | SCV000596670 | uncertain significance | not specified | 2017-03-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001857154 | SCV002287583 | uncertain significance | Martsolf syndrome; Warburg micro syndrome 2 | 2021-08-31 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid with asparagine at codon 1010 of the RAB3GAP2 protein (p.Asp1010Asn). The aspartic acid residue is moderately conserved and there is a small physicochemical difference between aspartic acid and asparagine. This variant is present in population databases (rs763047721, ExAC 0.1%). This variant has not been reported in the literature in individuals affected with RAB3GAP2-related conditions. ClinVar contains an entry for this variant (Variation ID: 436475). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |